Conditional financing of drugs in the Netherlands: past, present, and future—results from stakeholder interviews

Value in Health

8 April 2019 - It is long known that managed entry agreements may offer decision makers valuable policy options to share risks associated with the reimbursement of pharmaceutical drugs, whereby uncertainties may be present regarding their clinical effectiveness or cost effectiveness. 

Nevertheless, little is known on whether such managed entry agreements (MEAs) deliver on their potential benefits in practice. This is partly due to a lack of systematic evaluations of (previous or existing) MEAs in published literature.

This article presents a systematic evaluation of stakeholders' perspectives on the conditional financing of drugs in the Netherlands, one of the first MEAs in Europe.

Read Value in Health article

Michael Wonder

Posted by:

Michael Wonder